Mateon Therapeutics receives notice of partial clinical hold for OX1222 study
Mateon Therapeutics announced the FDA placed a partial clinical hold on Study OX1222 on Aug. 16, 2018. OX1222 is the Company's clinical trial of OXi4503 in combination with cytarabine for treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. August 17, 2018